LPL Financial LLC Sells 71,059 Shares of OPKO Health, Inc. (NASDAQ:OPK)

LPL Financial LLC trimmed its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 68.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,132 shares of the biotechnology company’s stock after selling 71,059 shares during the period. LPL Financial LLC’s holdings in OPKO Health were worth $49,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of OPK. Tejara Capital Ltd boosted its stake in OPKO Health by 11.3% during the fourth quarter. Tejara Capital Ltd now owns 1,225,650 shares of the biotechnology company’s stock worth $1,802,000 after acquiring an additional 124,524 shares in the last quarter. PFG Investments LLC lifted its stake in shares of OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock valued at $1,707,000 after buying an additional 99,795 shares in the last quarter. Barclays PLC increased its position in shares of OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares during the period. Essential Planning LLC. bought a new stake in OPKO Health during the fourth quarter valued at $506,000. Finally, Raymond James Financial Inc. bought a new position in shares of OPKO Health in the 4th quarter worth $221,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

OPK has been the subject of several analyst reports. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research report on Friday, April 25th. They set a “neutral” rating on the stock. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Finally, StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, OPKO Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $2.75.

OPKO Health Trading Down 2.2 %

Shares of OPKO Health stock opened at $1.35 on Friday. The company’s fifty day simple moving average is $1.62 and its 200-day simple moving average is $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 1-year low of $1.15 and a 1-year high of $2.04. The stock has a market capitalization of $906.59 million, a PE ratio of -7.11 and a beta of 1.78.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. OPKO Health’s revenue was down 13.7% on a year-over-year basis. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock in a transaction dated Thursday, April 10th. The shares were purchased at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the completion of the acquisition, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. This represents a 0.06 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders bought 767,434 shares of company stock worth $1,238,312 in the last quarter. 49.69% of the stock is owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.